Campath-1H + FK506 and Methylprednisolone for GVHD
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
- Status
- TERMINATED
- Phase
- PHASE3
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
- Status
- TERMINATED
- Phase
- PHASE1
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
- Status
- COMPLETED
- Phase
- PHASE2
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
- Status
- UNKNOWN
- Phase
- PHASE2
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
- Status
- COMPLETED
- Phase
- NA
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1